AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02611245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: This group of patients accepted intravenous injection from 0.5mg / kg to 5mg / kg ICG within 4 to 24 hours before surgery. All patients under general anesthesia to accept conventional thoracoscopy or thoracotomy. After entering the chest using fluorescence thoracoscopy system to collect the fluorescence and white-light images and record the video. After following the routine preoperative planning surgery, the researchers will carefully assess the possibility of the benign and malignant nodules and to communicate with the families of patients. If the patient's family expressed their willingness to dissect the nodules, the researchers will remove this extra pulmonary nodules. Resected specimens will send to routine pathological confirmation compared with the fluorescence results.
Study NCT02317094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood-flow restricted training
Description: The intervention consists of low-intensity blood-flow restricted training involving 5 lower extremity exercises performed uni lateral in four sets to concentric failure with an intensity of approximately 25 repetition maximum (25RM).
Study NCT02317094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Care as usual
Description: The intervention consists of various DMARDs, which are given to the patients depending on their physical state and the disease activity.
Study NCT02317094 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Care as usual
Description: The intervention consists of various DMARDs, which are given to the patients depending on their physical state and the disease activity.
Study NCT01572831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCT and clinical algorithm for stopping abx
Description: In the experimental arm, antibiotics will be stopped based upon the PCT-guided algorithm. This PCT algorithm also incorporates clinical parameters to ensure utmost safety for the patients. These clinical parameters are; resolution of fever (temperature less than 38.3 and greater than 36.0), shock (on no vasopressors), and leukocytosis (\<12,000 and >4,000).
Study NCT00515970 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shave excision
Description: Shave excision with a safety margin, using a scalpel. Wound healing by secondary intention. Preparation with paraffin. Parallel vertical bread loaf sections for histology. Staining with hematoxylin-eosin. Histologic diagnosis. Comment on complete removal (R0 versus R1). In case of R1 excision a reoperation is performed until R0 is achieved.
Study NCT00515970 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Curettage
Description: Curettage with a 7 mm ring curette with the potato-peeler technique (http://www.biopsypunch.com/kuerettagetechnik.htm; accessed on March 13, 2008). The handle of the curette is held in the distal inter-digital fold of the index finger, and supported by the other fingers of the curetting hand. The thumbs serve to provide a stable base. This technique makes it possible to guide the instrument, applying greater pressure, but accuracy is reduced. After macroscopically complete removal, a safety margin is removed with the curette. It is used for histology to distinguish between R0 (excision margin without tumor cells) and R1 resection (excision margin containing tumor cells). Preparation with paraffin. Parallel, vertical sections for histologic diagnosis. Hematoxylin-eosin staining.
Study NCT02286297 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miller
Description: Direct laryngoscopy
Study NCT01444664 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Clipping of Aneurysm
Description: Surgical clipping of intracranial aneurysm
Study NCT03939702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-986177
Description: An orally administered anticoagulant to prevent and treat thromboembolic events
Study NCT03815500 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Education
Description: Enhanced educational curriculum will involve learning modalities including 3D modeling, video, and visual-aid enhanced text for references to improve caregiver and patient understanding of wound packing techniques.
Study NCT00486746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (physical activity and dietary counseling)
Description: One-year intervention
Study NCT00486746 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General information on healthy lifestyle habits
Description: A single session
Study NCT02972970 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Aveera
Description: Subjects will use the 3D crafted CPAP mask. All subjects will receive a mask to use
Study NCT00884793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raltegravir
Description: The baseline ART regimen will be intensified with raltegravir 400mg orally (PO) twice daily (BID) (all participants) +/- a study NNRTI or protease inhibitor (PI) (at the option of the participant and the study clinical team).
Study NCT00884793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study NNRTI
Description: Subjects who are not already on an NNRTI and who are suitable candidates will have the option of adding a study NNRTI (either efavirenz or etravirine).
Study NCT00884793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study PI
Description: Subjects who are not on a PI and who are suitable candidates will have the option of adding a study PI. PIs used as study drugs will include atazanavir (+/- ritonavir), fosamprenavir (+/-ritonavir), lopinavir/ritonavir, and darunavir/ritonavir.
Study NCT01372618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM 230 / Pasireotide
Description: SOM230/Pasireotide is a multi-receptor targeted somatostatin analogue. In this trial, 600 mcg of SOM230/Pasireotide are taken twice daily subcutaneously.
Study NCT02061384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13-cis retinoic acid
Description: Accutane is used for the treatment of severe acne
Study NCT02061384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: Calcitriol is a form of vitamin D given twice daily (BID)
Study NCT01264302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: Finasteride Tablets 5 mg
Study NCT01264302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride
Description: Finasteride Tablets 5 mg
Study NCT02154893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound plus Laser and therapeutic exercise
Description: Ultrasound with frequency 1 Mhz and infrared laser with output power at 100 mW. The resistance training was performed.The treatments are done once a week, for 3 months.
Study NCT02154893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound plus Laser
Description: Ultrasound with frequency 1 Mhz and infrared laser with output power at 100 mW. The treatments are done once a week, for 3 months.
Study NCT00774735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: 30 mg given in combination with lopinavir/ritonavir
Study NCT00774735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: 30 mg in combination with darunavir/ritonavir
Study NCT05330663 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low protein diet with Fresubin® renal
Description: Low protein diet with Fresubin® renal Dosage: 1 bottle per day as a replacement for one regular meal. All patients will get individualized dietary counseling aimed at achieving a protein intake of 0.6-0.8 g/kg actual body weight/day and an energy intake of 30-35 kcal/kg actual body weight.
Study NCT05330663 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low protein diet with normal food
Description: All patients will get individualized dietary counseling aimed at achieving a protein intake of 0.6-0.8 g/kg actual body weight/day and an energy intake of 30-35 kcal/kg actual body weight/day.
Study NCT01335711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChronVac-C + SOC
Description: IMP: I.m. administration of 500 μg plasmid DNA vaccine CHRONVAC-C (solution for injection) administered i.m. in combination with electroporation using MedPulser® DDS on 2 occasions with 4 weeks in between followed by standard of care (SOC) initiation after 14 - 42 days.~SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of \< 75 kg and 1200 mg/day for subjects with a BW of > 75 kg)
Study NCT01335711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of \< 75 kg and 1200 mg/day for subjects with a BW of > 75 kg)
Study NCT00262834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally, conventional surgery to follow.
Study NCT00262834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Undergo conventional surgery
Study NCT01772992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CVCTPLUS
Description: For the intervention, couples will receive HIV testing and counseling together as a dyad, and some couples will receive ARV adherence counseling (Partner-STEPS) together as a dyad.
Study NCT00003457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Adults with a persistent or recurrent brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
Study NCT01492881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Oral, 400mg, taken days 4 through 11 of each cycle.
Study NCT01492881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: subcutaneous injection, 1.3mg/m2, Days 1, 4, 8, and 11 every cycle
Study NCT01492881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin
Description: Intravenous, 30mg/m2, Day 4
Study NCT04108546 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture device
Description: The technical characteristics of the device will be: power supply with alkaline batteries (4 pieces), 6V voltage, 6 independently regulated channels, symmetrical biphasic rectangular pulse, excitation from pen type electrode 0.48mA, with high 0.32mA + / -25% \& low 0.16mA +/- 25%. Three preset programs to avoid tolerance effect: program 1) 1-6Hz, program 2) 30-100Hz, program 3) 2-100Hz. Low frequencies (2Hz) cause release of endorphins in the brain and enkephalins in the spinal cord, high frequencies (30-100Hz) cause release of dynorphins in the spinal cord, while medium frequencies (15Hz) cause simultaneous release of endorphin and dynorphin. At low frequencies slow diffuse analgesia is achieved with a long duration of analgesic effect, while at high frequencies rapid local analgesic effect of short duration is achieved.
Study NCT04108546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia
Description: Ropivacaine (Naropeine) 0.2%, 5-7% ml, and Fentanyl 25mcg
Study NCT00709163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nesiritide
Description: The patient will be given an initial bolus of 1mcg/kg and then placed on a continuous infusion of 0.01mcg/kg/min. Three hours after the start of the infusion the patient will be rebolused with 1mcg/kg and increase the continuous infusion to 0.015mcg/kg/min. This will occur again at 6 hours after the start with an increase in the continuous infusion rate to 0.02mcg/kg/min. Patients will continue on the study drug for a total of 24 hours.
Study NCT00709163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Dextrose
Description: The patient will be given an initial bolus of 1mcg/kg and then placed on a continuous infusion of 0.01mcg/kg/min. Three hours after the start of the infusion the patient will be rebolused with 1mcg/kg and increase the continuous infusion to 0.015mcg/kg/min. This will occur again at 6 hours after the start with an increase in the continuous infusion rate to 0.02mcg/kg/min. Patients will continue on the study drug for a total of 24 hours.
Study NCT03399110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: oxaliplatin 130 mg/m2
Study NCT03399110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: oxaliplatin 130 mg/m2
Study NCT03399110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000mg/m2
Study NCT03399110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000mg/m2
Study NCT01407185 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistive Exercise Training
Description: Resistive Exercises (between 8 and 12 exercises for both upper and lower body) at 30 to 60% of 1 RM for 2x per week for 12 months.
Study NCT01245595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminophylline
Description: 5 mg/kg IV bolus then 1.8 mg/kg IV Q6 hours
Study NCT01245595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study NCT01151670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: Pioglitazone 22.5 mg daily before, during and after radiation therapy.
Study NCT01151670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 45 mg by mouth daily before, during and after radiation therapy
Study NCT02464059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Oral supplementation with 50,000 IU vitamin D3 weekly for eight weeks in individuals with reduced vitamin D levels.
Study NCT03454100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multisectoral package of activities
Description: A multi-sectoral package of village level activities, including having a well dug, a shared latrine installed, training on handwashing and hygiene across the water chain, training on conservation agriculture techniques, care groups for pregnant and breastfeeding mothers, and training on market gardens.
Study NCT01637012 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation
Description: index angioplasty with ALEX stent implatation
Study NCT00086346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus (Rapamune)
Study NCT00086346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine or Tacrolimus
Study NCT02286544 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Salmonella typhi vaccine (Typhim Vi®)
Description: A peripheral venous catheter will be inserted. This catheter will be used to collect blood sample during the study day. In addition, peripheral oxygen saturation will be measured by pulse oximetry. After baseline venous blood samples have been collected, all study participants will receive 0.5 mL of the Salmonella typhi vaccine as an intramuscular injection (Typhim Vi®, Sanofi Pasteur MSD, injection solution 25 microgram/0.5 mL) Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended.
Study NCT02286544 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Salmonella typhi vaccine (Typhim Vi®)
Description: A peripheral venous catheter will be inserted. This catheter will be used to collect blood sample during the study day. In addition, peripheral oxygen saturation will be measured by pulse oximetry. After baseline venous blood samples have been collected, all study participants will receive 0.5 mL of the Salmonella typhi vaccine as an intramuscular injection (Typhim Vi®, Sanofi Pasteur MSD, injection solution 25 microgram/0.5 mL) Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended.
Study NCT02286544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen (Oxymask®)
Description: As in arm 1. Half an hour after vaccination is administered, oxygen treatment will be initiated at 6 L/min via Oxymask® and continued for 6 hours. During oxygen treatment peripheral oxygen saturation will be measured by pulsoximetry.~Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended.
Study NCT02286544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: As in arm 1. Half an hour after vaccination is administered, oxygen treatment will be initiated at 6 L/min via Oxymask® and continued for 6 hours. During oxygen treatment peripheral oxygen saturation will be measured by pulsoximetry. A single dose of Atorvastatin 80 mg will be given immediately prior to start of oxygen. Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended.
Study NCT02416791 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic Therapy
Description: Robotic therapy (MIT - Manus, Interactive Motion Technologies) will be administered for 40 minutes to the paretic upper limb.
Study NCT02154893 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Utrasound plus Laser Placebo
Description: The device with Ultrasound and infrared laser without emitting electromagnetic or mechanical waves was applied (null dose).
Study NCT00919061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine: 800 mg/m\^2 over 30 minutes IV, weekly for 2 weeks, followed by a week off treatment.
Study NCT00919061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 20 mg /m\^2 over 30 minutes IV, weekly for 2 weeks, followed by a week off treatment.
Study NCT00919061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg PO once a day continuously.
Study NCT01655433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Velomedix APLS device
Description: Velomedix, Automated Peritoneal Lavage System
Study NCT01655433 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Hypothermia Treatment
Study NCT01190826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASM-024
Description: Target dose of 10 mg ASM-024 administered once by inhalation
Study NCT01190826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASM-024 100 mg
Description: Target dose of 100 mg ASM-024 administered once by inhalation
Study NCT01190826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered once by inhalation
Study NCT03354156 — intervention group
Intervention type: DRUG
Intervention: statin treatment
Description: The patients with elevated LDL receive statin treatment in the context of normal patient care (so this is NOT an intervention of the study)
Study NCT04346290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Initial infusion dose of dexmedetomidine is 0.4 mcg/kg/min, maintenance infusion dose is 0.1-0.7 mcg/kg/min
Study NCT03690986 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VX15/2503
Description: Given IV
Study NCT03690986 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT03690986 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02416791 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: Active tDCS will be applied with the cathode positioned over the ipsilesional primary motor cortex and the anode over the contralateral supraorbital region for 20 minutes (1mA).
Study NCT02416791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: In sham tDCS, no current will be delivered through the tDCS device.
Study NCT03242993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-AzaFol
Description: \[18F\]-AzaFol is a radiotracer produced at ETH Hönggerberg in a radiopharmaceutical GMP facility. The drug product is provided as sterile solution for intravenous injection in a glass vial containing 6 mL of formulated product, the maximal applicable dose being 600 MBq.
Study NCT03242993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folarell
Description: For the purpose of this study only 1 mg folic acid (corresponding to 0.2 mL Folarell®) will be injected 5 min prior to \[18F\]-AzaFol. Due to this low dose of a single injection of folic acid it is unlikely that adverse events would occur.~Folarell® is a folic acid preparation for intravenous or intramuscular injection
Study NCT00115258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: parenteral nutrition titrated to measured REE
Study NCT03765944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus
Description: SIngle administration under fasted condition
Study NCT00149552 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: zinc
Description: supplementation with zinc gluconate
Study NCT00149552 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: zinc
Description: supplementation with zinc gluconate
Study NCT02343562 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Probiotics in the form of sachet will be given twice daily for a period of at least 6 months during the trial period.
Study NCT02343562 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multivitamin off-the-counter.